SCHEMBL5832463

SCHEMBL5832463

Cc1ccc(-c2nc3ccccc3o2)cc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.59
RAB9A P51151 8/20 0.59
ALDH1A1 P00352 7/20 0.59
HPGD P15428 7/20 0.59
KDM4E B2RXH2 6/20 0.59
SMN1; SMN2 Q16637 6/20 0.59
MAPT P10636 5/20 0.59
HSD17B10 Q99714 3/20 0.59
HCRTR1 O43613 2/20 0.59
USP2 O75604 1/20 0.59
TSHR P16473 1/20 0.59
MAPK1 P28482 1/20 0.59
CASP3 P42574 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
SENP8 Q96LD8 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
SENP6 Q9GZR1 1/20 0.59
NFKB1 P19838 2/20 0.57
STAT1 P42224 2/20 0.57
NFKB2 Q00653 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11320611 0.88 NPC1 (0.59) NPC1RAB9AALDH1A1HPGDKDM4E
SCHEMBL3317791 0.84 KDM6B (0.63) NPC1RAB9AALDH1A1HPGDKDM4E
SCHEMBL2493904 0.82 NPC1 (0.64) NPC1RAB9AALDH1A1HPGDKDM4E
SCHEMBL11697224 0.82 NPC1 (0.59) NPC1RAB9AALDH1A1HPGDKDM4E
SCHEMBL5832955 0.82 MAPT (0.63) NPC1RAB9AALDH1A1HPGDKDM4E
SCHEMBL5831975 0.82 NPC1 (0.68) NPC1RAB9AALDH1A1HPGDKDM4E
SCHEMBL11326576 0.81 NPC1 (0.55) NPC1RAB9AALDH1A1HPGDKDM4E
SCHEMBL30959735 0.81 NPC1 (0.53) NPC1RAB9AALDH1A1HPGDKDM4E
SCHEMBL10069500 0.80 NPC1 (0.60) NPC1RAB9AALDH1A1HPGDKDM4E
SCHEMBL5832580 0.79 NPC1 (0.79) NPC1RAB9AALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087601-B2 Metabotropic glutamate receptor-5 modulators MERCK & CO., INC. (US) 2006-08-08 US disclosed
EP-1453815-A4 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO INC (US) 2005-04-06 EP disclosed
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators MERCK SHARP & DOHME CORP. 2005-03-24 US disclosed
EP-1453815-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS Merck & Co., Inc. (US) 2004-09-08 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003048137-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO., INC. (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators GRM5, GRIK5, GRM1 NPC1 3080/4885RAB9A 1104/4885ALDH1A1 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.